Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined

Authors

Z. Erjavec (ORCID: https://orcid.org/0000-0003-3450-9107)
John‐John B. Schnog (ORCID: https://orcid.org/0000-0001-9105-8248)
Ruben Van Dijck (ORCID: https://orcid.org/0000-0003-4748-7648)

Institutions

University of Curaçao (CW)

Publication Details

Journal: American Journal of Hematology
Published: 2025-05-29
DOI: https://doi.org/10.1002/ajh.27728
Primary Topic: Multiple Myeloma Research and Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined

Z. Erjavec, John‐John B. Schnog, Ruben Van Dijck

May 29, 2025

American Journal of Hematology

Multiple Myeloma Research and Treatments

article

Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined

Z. Erjavec, John‐John B. Schnog, Ruben Van Dijck

May 29, 2025article en

Abstract

No abstract available for this paper.

American Journal of HematologyVol. 100(8)

University of Curaçao (CW)

Zero hunger

Openalex Percentile: Top 85%

Multiple Myeloma Research and Treatments

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined — Z. Erjavec, John‐John B. Schnog, et al. · American Journal of Hematology (2025) | TGRS Research Map | TGRS